The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19.
Every two seconds someone in the U.S. needs blood. And according to the American Red Cross, a single donation can save up to three lives. On June 14, the National Heart, Lung, and Blood Institute (NHLBI) joins the World Health Organization (WHO) in observing World Blood Donor Day. Simone Glynn, M.D., M.P.H., chief of the Blood Epidemiology and...
Everyone responds to exercise differently. Now, researchers are reporting an advance toward a blood test that can help predict an individual’s best exercise choice for optimizing cardiorespiratory fitness.
The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in treating emergency department patients who developed mild to moderate symptoms of COVID-19, the disease caused by the coronavirus SARS-CoV-2.
NHLBI-supported researchers are reporting that COVID-19 triggers the production of certain autoimmune antibodies in the blood and that these antibodies are the culprit behind the formation of potentially life-threating blood clots in people hospitalized with the disease.